

Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes

“Double diabetes” in the Diabetes Control and Complications Trial

ERIC S. KILPATRICK, MD, FRCPATH¹
ALAN S. RIGBY, MSc²
STEPHEN L. ATKIN, PHD, FRCP³

OBJECTIVE — The presence of insulin resistance and the metabolic syndrome are known risk markers for macrovascular disease in patients with and without type 2 diabetes. This study has examined whether these also were predictors of micro- and macrovascular complications in type 1 diabetic patients participating in the Diabetes Control and Complications Trial (DCCT).

RESEARCH DESIGN AND METHODS — International Diabetes Federation (IDF) criteria were used to identify the metabolic syndrome in 1,337 Caucasian DCCT patients at baseline. Insulin resistance was calculated using their estimated glucose disposal rate (eGDR). Insulin dose (units/kg) was also used as a separate marker of insulin resistance.

RESULTS — The eGDR (but not insulin dose or metabolic syndrome) at baseline strongly predicted the development of retinopathy, nephropathy, and cardiovascular disease (hazard ratios 0.75, 0.88, and 0.70, respectively, per $\text{mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ change; $P < 0.001$, $P = 0.005$, and $P = 0.002$, respectively). Through mainly weight gain, the prevalence of the metabolic syndrome increased steadily from baseline to year 9 in conventionally treated (from 15.5 to 27.2%) and especially in the intensively treated (from 13.7 to 45.4%) patients.

CONCLUSIONS — Higher insulin resistance at baseline in the DCCT (as estimated by eGDR) was associated with increased subsequent risk of both micro- and macrovascular complications. Insulin dose and the presence of IDF-defined metabolic syndrome were poor predictors by comparison. Although intensive treatment was associated with a higher subsequent prevalence of metabolic syndrome, the benefits of improved glycemia appear to outweigh the risks related to development of the metabolic syndrome.

Diabetes Care 30:707–712, 2007

The metabolic syndrome is a cluster of metabolically related cardiovascular risk factors, the core components of which comprise of central obesity, insulin resistance, dyslipidemia, and hypertension (1). The presence of the metabolic syndrome predicts the risk of cardiovascular disease in nondiabetic subjects as well as in those with type 2 diabetes (2–6). There are multiple defini-

tions for the metabolic syndrome (7–9), with the most recent being the consensus from the International Diabetes Federation (IDF) (10).

Central to the development of the metabolic syndrome appears to be the presence of increased insulin resistance. Although this is a characteristic usually associated with the development of type 2 diabetes, it can also be a feature of patients

with type 1 diabetes (11–13). When present in type 1 diabetes, the phrase “double diabetes” has been coined (14), with the assumption that these patients are likely to be at especially high risk of developing cardiovascular disease.

Beyond the use of labor-intensive and invasive euglycemic-hyperinsulinemic clamp techniques, estimation of insulin resistance in type 1 diabetes is difficult because simpler tools such as the homeostasis model are not applicable for this group of patients (15). Clinically, insulin resistance in type 1 diabetic patients is often recognized by their larger requirements for insulin, but more recently a validated method for estimated glucose disposal rate (eGDR) has been developed (16). This calculates a score based on clinical factors of the patient, which shows a close relationship to insulin resistance when formally measured by the clamp method. Using this technique, data from the Pittsburgh Epidemiology of Diabetes Complications Study has found low eGDR (and therefore high insulin resistance) to be associated with an increased risk of nephropathy (17), peripheral vascular disease (18), and coronary artery disease (19). By comparison, few studies have looked at the metabolic syndrome itself in type 1 diabetes using current criteria. Data to date has shown that in a cross-section of type 1 diabetic patients there was an association between the presence of the metabolic syndrome and that of nephropathy and poor glycemic control (20).

The Diabetes Control and Complication Trial (DCCT) was performed at a time before patients with diabetes were routinely prescribed lipid-lowering and antihypertensive treatment (21). This means that it is a dataset that can investigate factors that influence the risk of developing diabetes complications while being free from many of the confounding factors found in contemporary studies. This current study has analyzed the DCCT data to establish how the metabolic syndrome, insulin resistance, and insulin

From the ¹Department of Clinical Biochemistry, Hull Royal Infirmary, Hull, U.K.; the ²Academic Department of Cardiology, University of Hull, Hull, U.K.; and the ³Department of Diabetes, Hull York Medical School, Hull, U.K.

Address correspondence and reprint requests to Prof. Eric S. Kilpatrick, Department of Clinical Biochemistry, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ. E-mail: eric.kilpatrick@hey.nhs.uk.

Received for publication 22 September 2006 and accepted in revised form 9 December 2006.

Abbreviations: DCCT, Diabetes Control and Complications Trial; eGDR, estimated glucose disposal rate; IDF, International Diabetes Federation; NCEP, National Cholesterol Education Program.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

DOI: 10.2337/dc06-1982

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Demographic and other baseline features

Variable	IDF metabolic syndrome	
	Yes	No
n	291	1,046
Age (years)	26.5 ± 7.5	27.0 ± 6.9
Waist circumference (cm)	96.1 ± 13.4	87.8 ± 10.2
BMI (kg/m ²)	24.7 ± 2.9	23.1 ± 2.7
HDL cholesterol (mmol/l)	1.08 ± 0.19	1.37 ± 0.32
Triglycerides (mmol/l)	1.13 ± 0.69	0.87 ± 0.48
Systolic blood pressure (mmHg)	115.3 ± 12.2	114.1 ± 11.4
Diastolic blood pressure (mmHg)	73.7 ± 9.4	72.5 ± 8.6
eGDR (mg · kg ⁻¹ · min ⁻¹)	7.4 ± 1.7	8.3 ± 1.3
A1C (%)	9.2 ± 1.6	8.8 ± 1.5
Blood glucose (mmol/l)	12.7 ± 5.3	12.0 ± 4.9

Data are means ± SD. A total of 54 subjects did not have waist circumference measured. A further 50 non-Caucasians were excluded.

dosage at trial baseline related to the subsequent risk of developing micro- and macrovascular complications in this group of patients with type 1 diabetes.

RESEARCH DESIGN AND METHODS

The datasets

We used the publicly accessible datasets collected by the DCCT, which was stored in SAS format (available at www.gcrc.umn.edu). The DCCT was a 9-year follow-up study of 1,441 participants with type 1 diabetes comparing the effect of intensive versus conventional blood glu-

cose management on the development of the microvascular complications of diabetes. The study participants were randomized into intensive (n = 711) and conventional (n = 730) treatment groups. The study did not include individuals at especially high cardiovascular risk, as both hypertension and severe dyslipidemia were exclusion criteria.

Definition of events

Severity of retinopathy was determined by the 25-point Early Diabetic Retinopathy Treatment Study interim score (21). The development and progression of sustained retinopathy was defined as a

change from baseline of three or more units on the Early Diabetic Retinopathy Treatment Study score on any two successive annual evaluations. During the 9 years of follow-up, 242 people developed sustained retinopathy, 67 of whom were in the intensive treatment group. Nephropathy was defined as an increase in albumin excretion rate ≥40 mg/24 h (28 µg/min) on any annual evaluation providing that the baseline albumin excretion rate was <40 mg/dl (28 µg/min) (22).

Cardiovascular events during the trial were those as defined as by the DCCT group and included angina, fatal and nonfatal myocardial infarction, coronary revascularization, and major electrocardiogram events (23). Analysis was performed on a time-to-first-event basis. In addition to these 31 initial events, there were another 73 macrovascular events including those affecting cerebrovascular and peripheral arteries.

Metabolic syndrome

Metabolic syndrome was defined according to the recent IDF consensus criteria (10). These criteria make central obesity essential for the diagnosis. Central obesity was defined as a waist circumference ≥94 cm (in male subjects), ≥80 cm (in female subjects), and/or a BMI ≥30 kg/m². Since we used the Europid definition for waist circumference, races other than Caucasians were excluded (n = 50). In addition to central obesity, the metabolic syndrome required the presence of any two additional criteria, namely raised triglycerides (>1.7 mmol/l), reduced HDL cholesterol (<1.03 mmol/l in male subjects and <1.29 mmol/l in female subjects), raised blood pressure (systolic ≥130 mmHg, diastolic ≥85 mmHg), or raised fasting plasma glucose (>5.6 mmol/l). All DCCT patients were assumed to fulfill the latter criterion. Although many of these risk factors are known to track with age (and many of the individuals in the DCCT were adolescents), none of the currently recommended definitions of metabolic syndrome (10) vary their thresholds according to subject age.

Waist circumference was only recorded at baseline, whereas BMI data were collected annually. To determine the prevalence of metabolic syndrome throughout the DCCT study period, we used a BMI threshold of ≥25 kg/m² instead (10). Indeed, the waist circumference cutoffs described above were originally chosen because they were felt,




Figure 1—Criteria in addition to raised waist circumference defining study patients at baseline as having the metabolic syndrome.

Table 2—IDF-defined metabolic syndrome by randomization group

Assessment	Intervention group	Total	Metabolic syndrome (n)	Relative risk (95% CI)
Baseline	Conventional	722	112	1.0
	Intensive	705	97	0.9 (0.7–1.1)
1 year	Conventional	715	122	1.0
	Intensive	694	141	1.2 (1.0–1.5)
2 years	Conventional	715	124	1.0
	Intensive	673	166	1.4 (1.2–1.8)
3 years	Conventional	708	128	1.0
	Intensive	654	176	1.5 (1.2–1.8)
4 years	Conventional	701	146	1.0
	Intensive	643	184	1.4 (1.1–1.7)
5 years	Conventional	616	124	1.0
	Intensive	549	196	1.8 (1.5–2.2)
6 years	Conventional	422	80	1.0
	Intensive	397	135	1.8 (1.4–2.3)
7 years	Conventional	265	70	1.0
	Intensive	246	98	1.5 (1.2–1.9)
8 years	Conventional	159	41	1.0
	Intensive	147	55	1.5 (1.0–2.0)
9 years	Conventional	125	34	1.0
	Intensive	119	54	1.7 (1.2–2.4)

Metabolic syndrome by IDF criteria, but using BMI ≥ 25 kg/m² to replace waist circumference, which was not measured annually.

based on Euroid data, to be the best values for identifying a BMI ≥ 25 kg/m² (10,24). The other IDF criteria remained unchanged.

While concentrating analysis on the IDF definition of metabolic syndrome, we also established which patients met the previous National Cholesterol Education Program (NCEP) Adult Treatment Panel III criteria (8). Obesity is not an absolute

requirement using the NCEP definition, but at least three risk factors are required from a possible five. Four of these five factors comprise raised triglycerides, reduced HDL cholesterol, raised blood pressure, and raised fasting plasma glucose using the same criteria as the IDF definition, but the fifth—waist circumference—uses thresholds that are greater




Figure 2—Prevalence of IDF-defined metabolic syndrome by randomization group throughout the study period. ■, intensively treated group; □, conventionally treated group.

(102 cm for male subjects and 88 cm for female subjects).

Insulin resistance and insulin dose

Insulin resistance was calculated using the eGDR according to the following equation: $24.31 - (12.22 \times \text{WH}) - (3.29 \times \text{HT}) - (0.57 \times \text{A1C})$, where the units are $\text{mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$, the WH = waist-to-hip ratio, and HT = hypertension (16). This formula has been adapted for the use of A1C rather than HbA_{1c} (20). Insulin dose was measured in units per kilogram body weight at baseline.

Statistical methods

The relationship between the baseline covariates and the time-to-event data (e.g., retinopathy development) was carried out by Cox proportional hazards modeling. Statistical modeling of time-to-event data are known in general terms as “survival analysis.” A distinguishing feature of survival data is that the end of the follow-up period will not have occurred in all patients. In such patients, the survival time is said to be “censored.” This censoring makes survival models difficult to analyze statistically (25) but was made possible by the theoretical development of the Cox proportional hazards model (26).

In the DCCT data the Cox model allows for the prediction of retinopathy from a given set of baseline covariates, such as eGDR and metabolic syndrome. The covariates may be continuous, binary, or categorical. The relationship between the covariates and retinopathy is expressed by the hazard ratio (HR) (essentially the risk of, say, retinopathy for a given covariate). A key statistical assumption is that the HR is constant over time (known as proportionality of hazards). This “proportionality” assumption can be tested by residual plotting (27). The precision of the HR is determined from the 95% CI; the narrower the CI the more precise the HR and vice versa. The *P* value, which represents the probability of a false-positive result, was calculated by the likelihood ratio test statistic, the calculation of which determines whether an association between a baseline covariate and retinopathy is random or not (albeit at an arbitrary level of 5%). The GLIM4 and SPSS statistical computer packages were used to analyze the data (28).

Table 3—Cox regression models relating metabolic syndrome and measures of insulin resistance to microvascular risk

Variable	Retinopathy	P value	Nephropathy	P value
Metabolic syndrome	0.85 (0.61–1.18)	0.33	0.98 (0.71–1.35)	0.91
eGDR	0.75 (0.69–0.81)	<0.001	0.88 (0.80–0.96)	0.005
Insulin dose	0.77 (0.41–1.45)	0.42	1.61 (0.93–2.82)	0.09

Data are HR (95% CI). Units for eGDR are $\text{mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ and for insulin dose are units per kilogram body weight. Models adjusted for the following baseline covariates: age, sex, disease duration, randomization treatment (conventional/intensive), and prevention cohort (primary/secondary).

RESULTS

Metabolic syndrome

Using the IDF criteria, 291 patients (22% of those with complete data and after excluding non-Caucasians) had metabolic syndrome at baseline; 1,046 did not have metabolic syndrome; 61 did not have their waist circumference recorded, 7 of whom had a $\text{BMI} \geq 30 \text{ kg/m}^2$. Thirty-two percent ($n = 93$) of patients with metabolic syndrome were male compared with 59% ($n = 620$) without metabolic syndrome. Other demographic features are presented in Table 1. Those without waist circumference recorded were younger (mean age 24.9 years) and had lower BMI on average (22.6 kg/m^2) than the rest, and 24 (44%) were male.

The Venn diagram (Fig. 1) shows which factors (raised blood pressure, high triglycerides, and low HDL cholesterol) classified patients as having the metabolic syndrome. Most patients had low HDL cholesterol ($n = 247$); a further 47 had high triglycerides, while 28 had raised blood pressure. Only one patient had all three of these criteria together.

The changing prevalence of the metabolic syndrome, using BMI rather than waist circumference criteria, are presented in Table 2 and Fig. 2. The prevalence of metabolic syndrome increases in both conventionally and intensively treated groups but at a statistically higher rate in the latter group from year 1 onwards. The baseline prevalence of $\text{BMI} \geq 25 \text{ kg/m}^2$ was 25.6% in the intensively treated group and 27.9% in the conventionally treated patients. This rose to 61.0 and 45.0%, respectively, by year 9 of the study. Mainly as a consequence of the higher waist circumference thresholds, fewer patients ($n = 114$) had metabolic syndrome at baseline when defined by NCEP criteria.

Insulin resistance and insulin dose

All subjects with a waist measurement also had a waist-to-hip ratio (20). The

mean (median) eGDR was $8.11 \text{ mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$ (8.21) (SD 1.49). One quarter ($n = 344$) had an eGDR >9.03 . The mean (median) dose of insulin at baseline was 0.67 units/kg (0.63) (range 0.08–2.06).

Cox regression

Multivariable Cox regression models for both microvascular and macrovascular risks are presented in Tables 3 and 4, respectively. After adjusting for insulin dose and the presence of metabolic syndrome, there was still a significant inverse association between lower eGDR at baseline and a subsequent increased risk of retinopathy and nephropathy progression (Table 2), cardiovascular events, and macrovascular disease (Table 3). By comparison, there were no significant relationships between baseline metabolic syndrome or insulin dose on microvascular or macrovascular disease risk. In addition, models that did not adjust eGDR, metabolic syndrome, and insulin dose for one another yielded similar results, as did further adjustment for smoking. Substituting the NCEP in place of the IDF definition of metabolic syndrome did not alter the findings either. The waist-to-hip ratio was measured at the iliac crest. Replacing this by the “natural” waist-to-hip ratio made little difference to the HRs. The eGDR did not seem to be superior to baseline A1C (itself a component of eGDR) for predicting any of the complications studied.

Subgroup analyses

We carried out Cox modeling stratifying by randomization group (excepting car-

diovascular diseases for which there were too few events). The relationship between eGDR and complication outcome was stronger in the conventionally treated group. The HR for any macrovascular disease in the conventionally treated group was 0.81 (0.70–1.00; $P = 0.05$) per unit change, with the HR in the intensive group 0.85 (0.70–1.04; $P = 0.11$). The HR for retinopathy in the conventionally treated group was 0.69 (0.62–0.76; $P < 0.001$), while in the intensive group was 0.83 (0.72–0.96; $P = 0.013$). The HR for nephropathy in the conventionally treated group was 0.84 (0.74–0.95; $P = 0.005$), while in the intensive group was 0.92 (0.80–1.06; $P = 0.24$). There were fewer micro- and macrovascular events in both groups separately (especially in the intensively treated patients), so any differences in statistical significance could be a function of reduced power.

CONCLUSIONS — This study has shown that DCCT patients with the highest insulin resistance at their baseline visit (as assessed by a low eGDR) were at the highest subsequent risk of developing the microvascular and macrovascular complications of type 1 diabetes, independently of their assigned treatment group. In comparison, the presence of the metabolic syndrome at the start of the study, defined using IDF criteria, showed little predictive value. Furthermore, a clinical estimate of insulin resistance—the insulin dose required by a patient in units per kilogram body weight—was also a poor predictor of future complications.

Our findings in relation to the value of the eGDR in predicting those patients at highest risk of small- and large-vessel disease are consistent with those from the Pittsburgh Epidemiology of Diabetes Complications Study. This prospective cohort study found low eGDR to be associated with the risk of nephropathy (17), peripheral vascular disease (18), and coronary artery disease (19). An analysis of the cross-sectional FinnDiane study also showed that type 1 diabetic patients with

Table 4—Cox regression models relating metabolic syndrome and measures of insulin resistance to macrovascular risk

Variable	Cardiovascular	P value	Any macrovascular	P value
Metabolic syndrome	1.15 (0.41–3.20)	0.79	1.15 (0.69–1.92)	0.60
eGDR	0.70 (0.56–0.88)	0.002	0.83 (0.73–0.96)	0.009
Insulin dose	3.35 (0.58–19.5)	0.18	1.45 (0.55–3.87)	0.45

Data are HR (95% CI). Notes: Models adjusted as in Table 3.

microalbuminuria had lower eGDR than those without but, in contrast to our findings, found the metabolic syndrome (defined using NCEP criteria [8]) to be more common in microalbuminuric patients as well (20).

The same study showed that the metabolic syndrome is a frequent finding in type 1 diabetes. We have confirmed this to be the case in the DCCT but have also found that as the study progressed the prevalence of the metabolic syndrome, using BMI rather than waist circumference criteria, increased markedly in both treatment groups. This was especially so in those treated intensively, which meant that by year 9 of the study three times as many intensively treated patients remaining had the metabolic syndrome than at baseline, resulting in nearly half the patients meeting the IDF criteria.

The bulk of this rise was due to the weight gain experienced during the study. Since it is known that patients with type 1 diabetes are at particularly high risk of cardiovascular disease already (29–31), there has been concern that this increase in body weight may only add to this likelihood, with intensively treated patients being placed at especial risk. Indeed, in the DCCT itself the excess weight gain with intensive therapy was associated with increases in visceral adiposity (32), which had consequent deleterious effects on lipids, blood pressure (33), and inflammatory markers (34). However, despite these concerns, the long-term follow-up study of the DCCT cohort (the Epidemiology of Diabetes Interventions and Complications) has found that intensive treatment during just the period of the DCCT greatly reduced, rather than increased, the long-term risk of cardiovascular disease by 42% (35). Differences in A1C during the DCCT (rather than simply changes in known cardiovascular risk factors) seemed to account for much of the benefit. Thus, together with the findings from other studies (36,37), it indicates that there is likely to be a net benefit to improving glycemic control in type 1 diabetes, even if there is resultant weight gain associated with it.

As a consequence, this study has identified a second reason why labeling a patient with type 1 diabetes as having the metabolic syndrome may be of limited use: not only was the presence of metabolic syndrome at baseline in the DCCT unrelated to micro- and macrovascular complications during the original study period but the group of patients most

likely to develop the metabolic syndrome during the course of the study were those least likely to have subsequent long-term microvascular and cardiovascular sequelae (35,38).

In its defense, the metabolic syndrome definition was never primarily intended for patients with type 1 diabetes, although there continues to be debate surrounding its value in other clinical situations for which it is proposed (39,40). Consideration also has to be given to the fact that the IDF definition of the metabolic syndrome may not be as specific as other criteria in identifying patients at high cardiovascular risk because of the lower waist circumference thresholds used (41). In respect of this current analysis, the NCEP definition of the metabolic syndrome at study baseline did not predict complication risk either, although this may be partly related to the fact that far fewer patients were identified when using these criteria.

In summary, this study has shown that the IDF definition of the metabolic syndrome appears to have little clinical utility in distinguishing type 1 diabetic patients most likely to develop micro- and macrovascular disease. Indeed, some patients who acquire this label might have done so through the pursuit of glycemic goals that may ultimately reduce their risk of complications. Assessing insulin resistance through the dosage of insulin taken by an individual was equally poor at predicting outcome. By contrast, assessing insulin resistance by calculating the eGDR identified type 1 diabetic patients who were at highest risk of subsequent small and large vessel disease.

Acknowledgments—We thank the DCCT investigators for making their trial dataset public and therefore allowing independent investigators to analyze their work for the benefit of patients with type 1 diabetes.

References

1. Reaven G: Banting Lecture 1988: Role of insulin resistance in human disease. *Diabetes* 37:1595–1607, 1988
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen M-R, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 24:683–689, 2001
3. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 288:2709–

- 2716, 2002
4. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DSJ, Haffner SM, Isles C, Macfarlane PW, Packard CJ, Cobbe SM, Shepherd J: Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. *Circulation* 108:414–419, 2003
5. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ: Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. *Circulation* 112:666–673, 2005
6. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H: The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. *J Clin Endocrinol Metab* 90:5698–5703, 2005
7. World Health Organization: *Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus: Report of a WHO Consultation*. Alwan AKH, Ed. Geneva, World Health Org., 1999, p. 1–59
8. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 285:2486–2497, 2001
9. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). *Diabet Med* 16:442–443, 1999
10. Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome: a new world-wide definition: a consensus statement from the International Diabetes Federation. *Diabet Med* 23:469–480, 2006
11. DeFronzo RA, Simonson D, Ferrannini E: Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. *Diabetologia* 23:313–319, 1982
12. DeFronzo RA, Hendler R, Simonson D: Insulin resistance is a prominent feature of insulin-dependent diabetes. *Diabetes* 31:795–801, 1982
13. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G: Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. *Lancet* 342:883–887, 1993
14. Teupe B, Bergis K: Epidemiological evidence for “double diabetes.” *Lancet* 337:361–362, 1991
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin con-

Downloaded from <http://diabetesjournals.org/care/article-pdf/30/3/707/595782/zdc00307000707.pdf> by guest on 22 July 2024

- centrations in man. *Diabetologia* 28:412–419, 1985
16. Williams K, Erbey J, Becker D, Arslanian S, Orchard T: Can clinical factors estimate insulin resistance in type 1 diabetes? *Diabetes* 49:626–632, 2000
 17. Orchard TJ, Chang Y-F, Ferrell RE, Petro N, Ellis DE: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? *Kidney Int* 62:963–970, 2002
 18. Olson JC, Erbey JR, Forrest KYZ, Williams K, Becker DJ, Orchard TJ: Glycemia (or, in women, estimated glucose disposal rate) predict lower extremity arterial disease events in type 1 diabetes. *Metabolism* 51:248–254, 2002
 19. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Smithline Kinder L, Ellis D, Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. *Diabetes Care* 26:1374–1379, 2003
 20. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Waden J, Ronnback M, Rosengard-Barlund M, Bjorkesten C-Ga, Taskinen M-R, Groop P-H, the FinnDiane Study Group: Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study) *Diabetes Care* 28:2019–2024, 2005
 21. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993
 22. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. *Kidney Int* 47:1703–1720, 1995
 23. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. *Am J Cardiol* 75:894–903, 1995
 24. Lean MEJ, Han TS, Morrison CE: Waist circumference as a measure for indicating need for weight management. *BMJ* 311:158–161, 1995
 25. Altman DG, Bland J: Time to event (survival) data. *Br Med J* 317:468–469, 1998
 26. Cox DR: Regression models and life-tables (with discussion). *J Royal Stat Soc Ser B* 34:187–220, 1972
 27. Schoenfeld D: Partial residual estimation for the proportional hazards regression model. *Biometrika* 69:239–241, 1982
 28. The GLIM System Release 4. Oxford, Clarendon Press, 1994
 29. Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL: The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: mortality results. *Diabetes* 33:271–276, 1984
 30. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia* 46:760–765, 2003
 31. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM: High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the General Practice Research Database. *Diabetes Care* 29:798–804, 2006
 32. Sibley SD, Palmer JP, Hirsch IB, Brunzell JD: Visceral obesity, hepatic lipase activity, and dyslipidemia in type 1 diabetes. *J Clin Endocrinol Metab* 88:3379–3384, 2003
 33. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. *JAMA* 280:140–146, 1998
 34. Schaumberg DA, Glynn RJ, Jenkins AJ, Lyons TJ, Rifai N, Manson JE, Ridker PM, Nathan DM: Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. *Circulation* 111:2446–2453, 2005
 35. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 353:2643–2653, 2005
 36. Williams K, Erbey J, Becker D, Orchard T: Improved glycemic control reduces the impact of weight gain on cardiovascular risk factors in type 1 diabetes: the Epidemiology of Diabetes Complications Study. *Diabetes Care* 22:1084–1091, 1999
 37. De Block CEM, De Leeuw IH, Van Gaal LF: Impact of overweight on chronic microvascular complications in type 1 diabetic patients. *Diabetes Care* 28:1649–1655, 2005
 38. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. *JAMA* 287:2563–2569, 2002
 39. Grundy SM: Does the metabolic syndrome exist? *Diabetes Care* 29:1689–1692, 2006
 40. Kahn R: The metabolic syndrome (emperor) wears no clothes. *Diabetes Care* 29:1693–1696, 2006
 41. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H: Adult Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. *Diabetes Care* 29:901–907, 2006